CD274 and neoplasm: Recent research has indicated that the concurrent inhibition of programmed death protein-1 (PD-1) with programmed cell death ligand-1 (PD-L1) and CD47/SIRP-α immune checkpoint pathways can amplify anti-tumor responses [8].